GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (MEX:NVS N) » Definitions » Cyclically Adjusted Price-to-FCF

Novartis AG (MEX:NVS N) Cyclically Adjusted Price-to-FCF : 18.54 (As of Jun. 30, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Novartis AG Cyclically Adjusted Price-to-FCF?

As of today (2025-06-30), Novartis AG's current share price is MXN2092.19. Novartis AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was MXN112.85. Novartis AG's Cyclically Adjusted Price-to-FCF for today is 18.54.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

MEX:NVS N' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 15.04   Med: 18.11   Max: 21.78
Current: 19.48

During the past years, Novartis AG's highest Cyclically Adjusted Price-to-FCF was 21.78. The lowest was 15.04. And the median was 18.11.

MEX:NVS N's Cyclically Adjusted Price-to-FCF is ranked better than
67.38% of 325 companies
in the Drug Manufacturers industry
Industry Median: 31.18 vs MEX:NVS N: 19.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novartis AG's adjusted free cash flow per share data for the three months ended in Mar. 2025 was MXN22.236. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is MXN112.85 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted Price-to-FCF Chart

Novartis AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.18 17.82 17.77 18.21 18.26

Novartis AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.51 19.88 19.74 18.26 19.82

Competitive Comparison of Novartis AG's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted Price-to-FCF falls into.


;
;

Novartis AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Novartis AG's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=2092.19/112.85
=18.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novartis AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=22.236/107.7224*107.7224
=22.236

Current CPI (Mar. 2025) = 107.7224.

Novartis AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 11.958 100.464 12.822
201509 16.260 99.785 17.553
201512 22.659 99.386 24.560
201603 5.980 99.475 6.476
201606 18.763 100.088 20.194
201609 18.603 99.604 20.119
201612 24.200 99.380 26.232
201703 11.751 100.040 12.653
201706 23.073 100.285 24.784
201709 22.441 100.254 24.113
201712 24.060 100.213 25.863
201803 14.243 100.836 15.216
201806 28.972 101.435 30.768
201809 25.673 101.246 27.315
201812 26.135 100.906 27.900
201903 14.870 101.571 15.771
201906 21.992 102.044 23.216
201909 34.353 101.396 36.496
201912 23.741 101.063 25.305
202003 20.921 101.048 22.303
202006 35.154 100.743 37.589
202009 24.269 100.585 25.991
202012 25.971 100.241 27.909
202103 11.479 100.800 12.267
202106 31.164 101.352 33.123
202109 40.011 101.533 42.450
202112 30.194 101.776 31.958
202203 7.032 103.205 7.340
202206 28.862 104.783 29.672
202209 39.206 104.835 40.286
202212 32.641 104.666 33.594
202303 21.834 106.245 22.138
202306 21.915 106.576 22.151
202309 39.413 106.570 39.839
202312 14.437 106.461 14.608
202403 8.952 107.355 8.983
202406 37.133 107.991 37.041
202409 53.301 107.468 53.427
202412 31.803 107.128 31.979
202503 22.236 107.722 22.236

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (MEX:NVS N) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Novartis AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Novartis AG Headlines

No Headlines